- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00207077
Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors
October 26, 2015 updated by: Eli Lilly and Company
A Phase I Study of Cetuximab in Combination With Erlotinib in Patients With Advanced Solid Malignancies
The purpose of this study is to find a safe and effective dose of the combination of cetuximab (Erbitux) and Tarceva (erlotinib).
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
33
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Delaware
-
Newark, Delaware, United States, 19718
- Christiana Care Health Services, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Measurable disease
- Life expectancy of at least 3 months
- Must have at least one prior chemotherapy containing a platinum
Exclusion Criteria:
- Known or documented brain metastases
- Prior cetuximab therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
|
IV solution + tablet, IV+ oral, ERB 100 mg/m2, 200 mg/m2, 250 mg/m2 IV + Erl 150 mg tablet, ERB weekly/ Erl once daily, Until disease progression.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Safety and efficacy of the combination of Tarceva and Erbitux
|
Secondary Outcome Measures
Outcome Measure |
---|
Radiographic response
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2005
Primary Completion (Actual)
May 1, 2007
Study Completion (Actual)
May 1, 2007
Study Registration Dates
First Submitted
September 12, 2005
First Submitted That Met QC Criteria
September 12, 2005
First Posted (Estimate)
September 21, 2005
Study Record Updates
Last Update Posted (Estimate)
October 28, 2015
Last Update Submitted That Met QC Criteria
October 26, 2015
Last Verified
October 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CA225-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
GlaxoSmithKlineCompleted
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
John M. BuattiNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedUterine Cervical Neoplasms | Prostatic Neoplasms | Rectal Neoplasms | Endometrial Neoplasms | Anus NeoplasmsUnited States
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
GlaxoSmithKlineRecruitingColonic Neoplasms | Neoplasms, ColonUnited States, Finland, France, Italy, Japan, Netherlands, Norway, Spain, Taiwan, United Kingdom, Australia, Belgium, Brazil, Germany, Greece, Sweden, Turkey, Canada, Korea, Republic of, Argentina, Hungary, Estonia, Portugal, Mexico, Pa...
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands
-
Russian Society of Colorectal SurgeonsRecruitingNeoplasms,ColorectalRussian Federation
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Novartis PharmaceuticalsBayerCompletedColorectal Neoplasms | Rectal Neoplasms | Colonic NeoplasmsUnited States, Germany, Belgium, Canada, Spain, United Kingdom, Taiwan, France, Switzerland, Sweden, Portugal, New Zealand, Italy, Slovakia, Australia, Austria, Brazil, Hong Kong
Clinical Trials on Cetuximab + Erlotinib
-
Memorial Sloan Kettering Cancer CenterBristol-Myers SquibbCompletedLung AdenocarcinomaUnited States
-
University of California, DavisNational Cancer Institute (NCI)CompletedLung Cancer | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Regeneron PharmaceuticalsCompleted
-
AbbVie (prior sponsor, Abbott)CompletedAdvanced Solid Tumors
-
M.D. Anderson Cancer CenterCompleted
-
Austin HealthRoyal North Shore Hospital; Ballarat Health Services; Queen Elizabeth Hospital...UnknownMetastatic Colorectal CancerAustralia
-
National Cancer Institute (NCI)CompletedMetastatic Squamous Neck Cancer With Occult Primary | Small Intestine Lymphoma | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer | Gastrointestinal Stromal Tumor | Metastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Tongue Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer and other conditionsUnited States
-
Hoffmann-La RocheCompleted
-
Eli Lilly and CompanyTerminatedColorectal Cancer | Non-Small Cell Lung Cancer | Advanced Solid TumorUnited States, Australia
-
M.D. Anderson Cancer CenterWithdrawnAdvanced Cancers